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Shortly after World War II, coronary heart disease was recognized as an epidemic. Cardiovas-
cular disease (CVD) had become the leading cause of death in Western societies. This led to
the formation of the National Heart, Lung, and Blood Institute in the United States and initia-
tion of the seminal Framingham Heart Study in 1948. This population-based cohort study on
the etiology and consequences of CVD has shed light on many of the well-known causes of
CVD. In one of their initial publications in 1961, the investigators from the Framingham
Heart Study introduced the concept of “factors of risk in the development of coronary heart
disease”, nowadays known as traditional cardiovascular risk factors [1].
The identification of high blood pressure and cholesterol levels as causes of CVD led to
the idea of screening and treatment thereof in otherwise healthy persons, in order to halt
atherosclerosis and forestall the occurrence of cardiovascular events. Initial treatment recom-
mendations in the 1970s and 1980s were based on the levels of the specific risk factors, with
antihypertensive treatment recommended for “virtually all persons with a diastolic blood pres-
sure exceeding 105 mmHg” [2]. However, a gradual diversification then took place in preven-
tive cardiology: hypertension guidelines remained focused on blood pressure levels, whereas
cholesterol treatment guidelines moved towards more sophisticated approaches by recom-
mending pharmacological interventions informed by the individual’s cardiovascular risk
based on the presence and levels of multiple cardiovascular risk factors.
Current treatment guidelines
With the latest edition of the American College of Cardiology/American Heart Association
hypertension treatment guidelines, treatment targets have also become more individualized
based on cardiovascular disease risk, with lower blood pressure targets for patients with estab-
lished CVD or diabetes, as well as in those at a high 10-year predicted cardiovascular risk [3].
Yet, the indications for initiating blood pressure-lowering treatment remain primarily driven
by blood pressure levels, whereas for statin treatment, cardiovascular risk instead of cholesterol
level is the main driver of recommendations for treatment initiation. In this issue of PLOS
Medicine, Kazem Rahimi and colleagues, on behalf of the Blood Pressure Lowering Treatment
Trialists’ Collaboration, present an analysis of individual patient data indicating that, at the
population level, a strategy based on 5-year predicted cardiovascular risk—rather than blood







Citation: Leening MJG, Ikram MA (2018) Primary
prevention of cardiovascular disease: The past,
present, and future of blood pressure- and
cholesterol-lowering treatments. PLoS Med 15(3):
e1002539. https://doi.org/10.1371/journal.
pmed.1002539
Published: March 20, 2018
Copyright: © 2018 Leening, Ikram. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: CVD, cardiovascular disease.
Provenance: Commissioned; not externally peer
reviewed.
pressure levels alone—could be more effective, especially in a primary prevention setting [4].
For example, they report that compared with a strategy of treating everyone with a systolic
blood pressure of 140 mmHg or more, treatment based on overall CVD risk would prevent
3.1% more events (95% CI 1.5% to 5.0%) for the same number of people treated. These data
reemphasize that we should target overall cardiovascular risk and aim to modify risk through
holistic risk management, as opposed to targeting only individual risk factor levels in isolation.
Traditionally, the focus in cardiovascular risk assessment has been on 10-year probabilities
of developing CVD. However, such 10-year absolute cardiovascular risk estimates are often
abstract numbers to patients, and risk communication is therefore challenging, especially in
younger individuals with multiple risk factors in whom 10-year absolute cardiovascular risk
remains low by virtue of their age [5]. For this reason, in the latest iterations of the US and
British CVD prevention guidelines [6–8], attention is shifting towards lifetime perspectives.
This transition is driven by data demonstrating that cardiovascular risk is best expressed by
cumulative exposure to risk factors over time, rather than risk factor levels at a single time
point, and aggressive risk factor management should be considered earlier in life [5,6,9,10].
For example, duration of exposure to hypertension in early adulthood is associated with the
amount of coronary atherosclerosis in middle age [11]. Barriers towards a full transition from
10-year risk to lifetime risk in preventive cardiology include the lack of established treatment
thresholds and suboptimal performance of the available risk models [9].
Challenges and opportunities
With accruing evidence supporting safe generic medication for blood pressure and cholesterol
lowering, indications for treatment have been widened through drastic lowering of treatment
thresholds and targets. This is a consistent phenomenon across clinical practice guidelines in
high-income countries, to such an extent that nearly all individuals aged 65 years and over
now qualify for statin treatment [5,12]. Nonetheless, drug treatment comes with potential side
effects and costs. Hence, clinicians and policy makers should retain a healthy level of skepti-
cism towards unrestricted population-wide treatment. On the other hand, broadened indica-
tions and widespread use of blood pressure- and cholesterol-lowering medication should not
be erroneously labeled as unnecessary medicalization of society [13]: the burden of cardiovas-
cular risk factors remains very high because of unhealthy contemporary lifestyles and justifies
medical therapy in a substantial proportion of the population. Therefore, population-wide
screening programs for cardiovascular risk assessment could facilitate early detection of those
at high risk and identify individuals who would benefit most from early sustained blood pres-
sure- or cholesterol-lowering treatment. However, the optimal age at which to screen for car-
diovascular risk factors and subsequent age-specific treatment thresholds and targets are as yet
unknown [5,14].
Treatment recommendations from current risk-based prevention guidelines [6–8, 15–17]
do not directly reflect the evidence derived from clinical trials [12,18] but rather reflect gener-
alizations of findings derived from clinical trials showing greater absolute risk reduction in
those at higher observed cardiovascular risk. Very low-risk individuals may not be recom-
mended preventive treatment although trial evidence of statin efficacy is available for such
people [18]. Conversely, findings from trials of antihypertensives and statins are extrapolated
to high-risk individuals in whom the efficacy of preventive treatment has not been studied
[12,18]. For many of these high-risk individuals, it is highly unlikely that direct trial evidence
will ever be accrued, because not every specific patient group can be studied; therefore, extrap-
olation will always be necessary to some extent. A particularly vulnerable and understudied
group consists of persons with comorbidities associated with increased cardiovascular risk,
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including autoimmune, pulmonary, or liver diseases. Consequently, interactions with drugs
used to treat such conditions or disease-specific adverse effects of preventive treatment will
remain understudied. Similarly, direct trial evidence on the efficacy of preventive cardiovascu-
lar medication in such vulnerable populations will remain absent.
Patient involvement and shared decision-making between patients and physicians has
become an increasingly important aspect of CVD prevention. Anticipated cardiovascular risk
reduction with blood pressure- or cholesterol-lowering treatment should be weighed against
the burden and costs of taking medication, as well as potential adverse effects. In many indi-
viduals free of CVD, the risk of developing CVD is relatively low. Hence, patient preferences
and attitudes towards preventive medication are key to decisions to initiate or intensify treat-
ment. However, informed decisions rely on a good understanding of an individual’s cardiovas-
cular risk and risk reduction conferred by preventive treatment. Therefore, comprehensible
metrics are needed to summarize anticipated treatment benefit, for instance, by expressing
lifetime benefits of treatment as gains in CVD-free life expectancy [5,19].
Future directions
Recent decades have seen a transition from risk factor-based treatment to treatment based on
overall short-term and lifetime risk. The work by Rahimi and colleagues in PLOS Medicine
contributes evidence that risk-based allocation represents a more efficient approach towards
blood pressure-lowering treatment in primary prevention of CVD [4]. Now, we should move
further towards personalized treatment guidance based on anticipated benefit [5,19,20]. Antic-
ipated treatment benefit is related to absolute overall risk of CVD but is not simply a rescaling
of risk.
First, data from clinical trials on pharmacological interventions need to be incorporated
in the construction of estimates of anticipated treatment benefit [20–22]. For instance,
blood pressure- and cholesterol-lowering treatment remains effective at older age, yet the
relative risk reduction generally diminishes with age. Similarly, treatment effects may vary
by ethnicity, by specific risk factor levels, and by comorbidity, such as renal disease. For
example, let us compare 2 healthy men of similar age with identical 10-year cardiovascular
risk estimates. One man’s risk is driven by moderate hypertension, and the other man’s risk
by moderate hypercholesterolemia: it seems most reasonable to lower cardiovascular risk
with antihypertensives in the former and with statins in the latter [20]. Second, since preven-
tive treatment to lower blood pressure and cholesterol is often initiated with the intention of
being used for decades or even lifelong, life expectancy is a key variable in estimating antici-
pated benefit. For instance, smoking roughly doubles the risk of CVD, yet anticipated gains
in CVD-free life expectancy with lifelong statin therapy are similar for smokers and non-
smokers. This is caused by competing risks of smoking-related cancers and other life-limit-
ing diseases [19].
Combining information on demographics, risk factor levels, and data on relative risk reduc-
tions obtained from clinical trials can inform models to provide anticipated benefits expressed
as gains in CVD-free life expectancy with specific treatment options and thereby facilitate
more informed treatment decisions. Similar estimates of anticipated harms can be produced
for the risks associated with drug treatment. Healthcare policy makers can use such data to
project costs and benefits of treatment and thereby provide clinicians with generally acceptable
treatment thresholds.
CVD remains a leading cause of morbidity and mortality worldwide. Despite great progress
in treatment of acute cardiovascular conditions, first manifestations of CVD are still often
lethal or result in long-term disability. Therefore, optimal primary prevention should remain a
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priority in the future. More new strategies will emerge, and clinical practice guidelines are
likely to evolve from risk factor-based treatment to risk-based treatment and beyond to treat-
ment based on anticipated benefit. Throughout this process, cardiovascular specialists, general
practitioners, and researchers need to keep prioritizing time and resources to offer preventive
measures to healthy individuals free from CVD and focus on compliance and persistence with
treatment, irrespective of the prevention strategy chosen.
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